Nonoperative Management for Rectal Cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• The treatment landscape for locally advanced rectal cancer (LARC) has evolved, increasing in complexity over the last decade.
• Nonoperative management (NOM) is emerging as a viable alternative for select LARC patients who achieve a clinical complete response (cCR) post-neoadjuvant therapy.
• Increasing rates of cCR and patient-reported outcomes are driving the consideration of NOM.

Purpose of the Study:

• To highlight the growing acceptance and importance of nonoperative management (NOM) in locally advanced rectal cancer (LARC).
• To emphasize the critical need for accurate patient selection for NOM based on clinical complete response (cCR) after neoadjuvant therapy.
• To advocate for the inclusion of NOM in treatment discussions for LARC patients.

Main Methods:

• Review of current treatment paradigms for locally advanced rectal cancer.
• Analysis of the role and acceptance of nonoperative management (NOM) following neoadjuvant therapy.
• Discussion of criteria for identifying clinical complete response (cCR) in rectal cancer patients.

Main Results:

• Nonoperative management (NOM) is increasingly recognized as a treatment option for LARC patients.
• Accurate identification of clinical complete response (cCR) is the primary challenge in selecting candidates for NOM.
• NOM offers potential benefits including improved quality of life and avoidance of surgical morbidity.

Conclusions:

• Nonoperative management (NOM) should be a standard part of treatment discussions for locally advanced rectal cancer (LARC).
• Accurate patient selection for NOM, based on achieving a clinical complete response (cCR), is crucial for successful outcomes.
• NOM presents an opportunity to enhance patient quality of life and reduce surgical complications in LARC treatment.